Cowen & Co. Reaffirms Their Hold Rating on Sunesis Pharma (SNSS)


In a report released yesterday, Marc Frahm from Cowen & Co. maintained a Hold rating on Sunesis Pharma (SNSS). The company’s shares closed yesterday at $1.43.

According to TipRanks.com, Frahm is a 3-star analyst with an average return of 2.7% and a 54.5% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and Unum Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sunesis Pharma with a $0.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.87 and a one-year low of $0.20. Currently, Sunesis Pharma has an average volume of 821.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts